Panchkula, Nov. 6 -- Haryana has suspended 966 drug sale licences and 12 manufacturing and blood centre licences for regulatory violations during a six-month enforcement drive, a Food and Drug Administration (FDA) spokesperson said on Friday.
The action was taken following inspections conducted by the Drug Wing between April 1 and September 30, 2026. During this period, 13,590 drug sale establishments and 423 manufacturing units were inspected. Besides the suspensions, 15 licences were cancelled completely and five partially.
The spokesperson said 2,389 drug samples were collected during the period, of which 2,189 had been tested. Eleven samples were found to be substandard.
The department also initiated prosecution in 64 cases. Of the 1...